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Abstract
Objective: To summarize the recommendations on folate intake and folic acid
supplementation and fortiﬁcation in the periconceptional period, aimed at
prevention of neural tube defects (NTD), provided by ofﬁcial health organizations
in different countries worldwide and WHO.
Design: Information on recommendations for folate and folic acid intake in the
periconceptional period was gathered from the websites of ofﬁcial national health
organizations of several countries worldwide and from the WHO website.
Setting: WHO, selected developed countries and emerging economies, totalling
thirty-six countries worldwide (some European, BRICS, G8, Asian Tiger/Asian
Dragon and Australia).
Results: Recommendations differ between countries, although the majority
(69·4 %) recommend a healthy diet plus a folic acid supplement of 400 µg/d from
preconception (4–12 weeks) until the end of the ﬁrst trimester of pregnancy
(8–12 weeks). The same recommendation is issued by the WHO. Dosages for
women at high risk of NTD are up to 4–5 mg/d (for 41·7 % of studied countries).
The recommended intake for folate is in the range of 300–400 µg/d for women of
childbearing age and 500–600 µg/d for pregnant women in different countries and
WHO. Five countries emphasize the importance of a healthy diet rendering
supplementation needless. By contrast, ﬁve others advise a healthy diet and
supplementation plus mandatory fortiﬁcation. Only one mentions the importance
of ensuring an adequate folate status and refers to checking with a health-care
provider on the need for supplements.
Conclusions: Different recommendations regarding folate and folic acid, seeking
NTD prevention, are available worldwide; however, most countries and WHO
focus on a healthy diet and folic acid supplementation of 400 µg/d
periconceptionally.
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Ofﬁcial health organizations’
recommendations
Worldwide, more than 10 % of infant deaths secondary to
congenital anomalies are caused by nervous system
anomalies(1). Neural tube defects (NTD) are the most
common major congenital anomalies of the central ner-
vous system, constituting an important public health pro-
blem in terms of mortality, morbidity, social cost and
human suffering(2). The incidence of NTD ranges from 0·5
to 14 per 1000 live births(3).
The ﬁndings obtained from randomized trials by the
British Medical Research Council in 1991(4) and by the
Hungarian National Institute of Hygiene (a WHO Colla-
borating Centre for the Community Control of Hereditary
Diseases) in 1992(5) about the effect of periconceptional
folic acid supplementation on NTD prevention were
revolutionary and remain consensual to the present day(6).
Furthermore, folic acid seems to prevent other congenital
anomalies (cleft lip(7,8) and cardiovascular malformations),
but the results are not consistent(2,5,9,10). The relationships
between maternal folate levels and other pregnancy out-
comes, such as placental abruption, placental weight and
gestational age, also remain inconclusive(11–14).
Curiously, in two observational studies, folic acid sup-
plementation did not show any inﬂuence on trends of
incidence of NTD(15,16), probably because most women
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started supplementation after the target period(17). In order
to prevent NTD, and considering that the neural tube
closes by day 28(18) when most women do not know they
are pregnant(2), even in planned pregnancies, folic acid
supplementation should start before conception(6,19).
However, estimates indicate that 41 % pregnancies
worldwide are unintended(20).
Regarding these promising results provided by the
randomized trials, the water-soluble nature of folic acid
and the unawareness of adverse effects (apart from neu-
rological complications in people with vitamin B12 deﬁ-
ciency(6)), combined with the difﬁculty of global
supplementation in the desired period, fortiﬁcation of
foods with this vitamin has been considered safe(21). This
motivated some countries to opt for folic acid fortiﬁcation
of cereal products, namely ﬂour. Nowadays, fortiﬁcation
of ﬂour with folic acid is mandatory in forty-seven coun-
tries, in the continents of America and Oceania, in the
Middle East and a few in Africa(22,23). The effectiveness of
mandatory folic acid fortiﬁcation has been studied in some
countries and a signiﬁcant decline in prevalence of some
NTD was observed; for instance, after mandatory folic acid
fortiﬁcation in the USA and Canada, the occurrence of
some NTD declined by 28 %(24) and 46 %(25), respectively.
Nevertheless, part of this decline can be explained by
better prenatal screening and the termination of affected
pregnancies(26). Moreover, in a recent review, the authors
defended that women of childbearing age may not yet be
adequately targeted, while the general population may be
over-fortiﬁed with folic acid(27). Uncertainties remain over
the minimum effective folate intake and status required for
NTD prevention, and the safe upper folate level(27).
Voluntary fortiﬁcation is permitted in most European
countries, but none has mandatory fortiﬁcation(15).
Recently the EU introduced new rules to regulate volun-
tary food fortiﬁcation(15).
After mandatory folic acid fortiﬁcation, many questions
arose regarding individual liberty (to choose fortiﬁed or non-
fortiﬁed foods) and about feasible monitoring of potential
hazards of the fortiﬁcation(15). The possible carcinogenicity
of excessive intake of folic acid has been suggested(2,28),
supported by biologically plausible mechanisms: folate is
essential in biological methylation reactions and nucleotide
synthesis and impairment of these processes is thought to be
involved in cancer development(15). Some researchers sug-
gested that a link could exist between high folic acid intake
and cancer incidence(29,30), but this is not consensual(15,31,32).
Recently, a new concern has arisen regarding the
potential adverse effects of universal maternal supple-
mentation on adverse pregnancy outcomes, early or later
in life, both in the mother and child(13,33). Studies have
associated maternal folic acid supplementation with
increased birth weight(11–14), insulin resistance in chil-
dren(34) and asthma in children(35,36).
Overall, current evidence suggests that the relationship
between maternal folic acid supplementation and
pregnancy outcomes displays a U-shaped association,
with adverse effects at both low and high dosages. Ofﬁcial
health institutions should deliver clear and evidence-based
messages regarding folic acid intake in order to maximize
health gains and to minimize adverse effects.
The present study aimed to summarize the recommen-
dations on folate intake and folic acid supplementation
and fortiﬁcation, in the periconceptional period, aimed at
NTD risk reduction, provided by ofﬁcial health organiza-
tions in different countries worldwide and WHO. This
work could constitute a ﬁrst step of a global discussion
about the divergences between recommendations, in
order to improve them.
Methods
Data about folate (provided by diet) and folic acid (pro-
vided by supplements or fortiﬁed foods) recommenda-
tions in the periconceptional period were obtained from
national health ofﬁcial websites across forty-six countries
worldwide and from the WHO website. Eligibility criteria
for country selection, deﬁned by the research team, were
the following: EU countries (Austria, Belgium, Bulgaria,
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Fin-
land, France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Lithuania, Luxembourg, Malta, Netherlands,
Poland, Portugal, Romania, Slovakia, Slovenia, Spain,
Sweden and UK) and some European countries not
belonging to the EU (Iceland, Liechtenstein, Norway,
Switzerland and Turkey) that were mentioned on the
European Commission website, on the web page entitled
Public Health – Trustworthy websites on ‘Population
groups’ (37); BRICS countries (Brazil, Russia, India, China
and South Africa); Group of Eight (G8) countries (that
include some EU and BRICS countries already stated; they
are Canada, France, Germany, Italy, Japan, Russia, UK and
USA); Asian Tiger/Asian Dragon countries (Hong Kong,
Singapore, South Korea and Taiwan); and Australia.
Developed countries and emerging economies
(according to the UN, International Monetary Fund,
Organisation for Economic Co-operation and Develop-
ment, and World Bank) in well-deﬁned groups were
selected because of the easiest access to data.
The keywords used for searching in each country’s
websites were the following: folic acid, folate, pregnancy
and nutrition. These terms and the information found in
the countries’ websites were translated on Google®
Translate, from English to the ofﬁcial languages and vice
versa. Ministry of Health websites were chosen for their
national coverage of the recommendations. However, for
some countries we considered scientiﬁc organizations’
websites when mentioned or linked with the Ministry of
Health website.
Data extracted from each website covered the following
topics: (i) amount of recommended folate intake for
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women of childbearing age and pregnant women (mea-
sured in folate or dietary folate equivalents (DFE));
(ii) recommendation of a healthy diet and folate-rich
foods; and (iii) folic acid supplementation for NTD risk
reduction (recommended dosage, tolerable upper intake
level (UL), dosage for high risk of NTD, when to start and
to ﬁnish the supplementation). Data about mandatory folic
acid fortiﬁcation were obtained at the European Surveil-
lance of Congenital Anomalies (EUROCAT) website(23).
The names of the ofﬁcial entities, the types of information
(for health professionals or the general public) and
the website addresses were also registered for further
validation. Only nine countries (25·0 %) had all desired
information available (Australia, Austria, Denmark, Estonia,
Finland, Germany, Switzerland, Canada and USA).
Websites were chosen instead of collecting data from
scientiﬁc articles or sending emails to each national health
representative asking for information, because the found
reviews(16,38) did not include all the desired countries nor all
information. We also intended to ﬁnd which information is
available through the World Wide Web, where many people
(from health professionals to the general public) consult and
follow health recommendations(39–41). Information on
mandatory fortiﬁcation was collected only to complete this
overview, since we intended to summarize information that
could be searched by people and used to inﬂuence their
behaviours. Mandatory fortiﬁcation is a governmental deci-
sion that potentially affects the whole population.
Emails were sent for all forty-six selected countries in
order to obtain data validation or to obtain missing data
(data that could be on the website, but had not yet been
found). In the validation process, the information was
conﬁrmed, corrected and/or completed. Data without
ofﬁcial validation were equally considered for results and
analysis, after conﬁrmation from the websites on at least
three different days.
Data were collected from May until October 2013, and
updated in December 2014.
Results
From the forty-six countries initially considered, ten
(21·7 %) were excluded – six in the EU (Croatia, Cyprus,
Czech Republic, Greek, Lithuania and Slovakia), two
European countries not belonging to the EU (Liechtenstein
and Turkey), one BRICS country (India) and one Asian
Tiger/Asian Dragon country (South Korea) – on the basis
of data being unavailable or not found. Thus a ﬁnal sam-
ple of thirty-six countries was obtained: twenty-two in the
EU (Austria, Belgium, Bulgaria, Denmark, Estonia, Finland,
France, Germany, Hungary, Ireland, Italy, Latvia, Luxembourg,
Malta, Netherlands, Poland, Portugal, Romania, Slovenia,
Spain, Sweden and UK), three European countries not
belonging to the EU (Iceland, Norway and Switzerland), four
BRICS countries (Brazil, Russia, China and South Africa), three
more G8 countries (the other ﬁve were already stated in EU
and BRICS; Canada, Japan and USA), three Asian Tiger/Asian
Dragon countries (Hong Kong, Singapore and Taiwan) and
Australia; see Fig. 1.
Fig. 1 World map showing the thirty-six countries in which recommendations for folate and folic acid intake in the periconceptional
period were analysed (● , country with official validation; ∗ , country without official validation)
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From the thirty-six countries included, twenty-six
countries validated the information by email (72·2 %)
and ten did not (Brazil, China, France, Japan, Latvia,
Romania, Russia, Singapore, South Africa and Taiwan). From
the other ten countries without data, only Liechtenstein
validated the (missing) information. The WHO did not
validate data.
The recommendations for folate and folic acid intake in
the periconceptional period are synthesized in Table 1.
A healthy diet and/or folate-rich food recommendations
were issued by all countries (100·0 %), but the WHO
website only mentioned it for women with high risk of
NTD. Interestingly, ﬁve countries (13·9 %; Finland, France,
Sweden, Singapore and Taiwan) considered that a healthy
diet containing adequate amounts of folate may be
enough, with no need for supplementation. Three coun-
tries (Hong Kong, Slovenia and Sweden) published
e-leaﬂets for the general public with complete and
detailed information about healthy diet during pregnancy,
consumption of folate-rich foods, cooking methods and
quantities. Eight more countries (Austria, Denmark,
Estonia, France, Iceland, Luxembourg, Taiwan and Poland)
also published e-leaﬂets with information for pregnant
women including healthy diet. Some others mentioned it
directly on the website.
Concerning recommended folate intake (and estimated
average requirements) for women of childbearing age and
pregnant women, respectively, we identiﬁed three main
different recommendations: (i) Dietary Reference Intakes
from the US Institute of Medicine (IOM; followed by
22·2 % of countries), namely 400 µg/d and 600 µg/d
(320 µg/d and 520 µg/d); (ii) Nordic Nutrition Recom-
mendations from the Nordic Council of Ministers (NNR;
followed by 16·7 % of countries), namely 400 µg/d and
500 µg/d (200 µg/d); and (iii) reference values for the
nutrient intake from the dominant states of the German
language (Deutschland–Austria–Confoederatio Helvetica
(D-A-CH); followed by 8·3% of countries), namely 300 µg/d
and 550 µg/d (220 µg/d and 420 µg/d). WHO adopted the
folate recommendations from the IOM(28,42). About half of
the countries (52·8%) did not have any references regarding
recommended folate intake through diet. For Switzerland,
different values were available in the two sources consulted
(D-A-CH and those referred by the Swiss Federal Ofﬁce of
Public Health). Slovenia followed D-A-CH recommenda-
tions, with high values only after the ﬁrst trimester. This
appears more practicable as physiologically women have
higher energetic needs in the second and third trimesters(43),
notwithstanding the role of folate after the ﬁrst trimester is
not completely established. It is also apparent that NNR
presented the smallest increase from preconception to
pregnancy, possibly more attainable. The highest values
from the IOM seem less achievable than those from D-A-CH
or NNR.
Regarding folic acid supplementation for NTD preven-
tion, the majority (n 33, 91·7 %) of the analysed countries
have some information on their national health ofﬁcial
websites about this topic. Most countries (80·6 %) recom-
mend a folic acid supplement of 400 µg/d, two countries
state that the dosage should be recommended by a health-
care provider (without mentioning any dosage) and one
country recommends 5mg/d. Concerning the time for
initiating the supplementation, 33·3 % of countries state at
least 4 weeks before conception, as settled by D-A-CH
recommendations; 27·8 % of countries state that ‘supple-
mentation should begin when planning pregnancy’ or
‘when there is a chance to become pregnant/capable of
becoming pregnant’, as stressed by the IOM recommen-
dations; 13·9 % of countries mention at least 12 weeks
before pregnancy; two countries refer to 4–8 weeks or
8–12 weeks before conception; two advocate to start
when contraception is stopped; and one country recom-
mends at least 8 weeks before stopping contraception.
Most countries (75·0 %) consider that supplementation
should be maintained until the end of the ﬁrst trimester
(12 weeks) or almost (10 or 8–12 weeks), but three
countries (Canada, China and USA) recommend supple-
mentation until the end of pregnancy.
On the subject of the UL, 44·4 % of countries and two
entities (D-A-CH and IOM) state 1 mg/d and two countries
appeal for not exceeding the recommendations without
mentioning the UL. Finally, the dosages recommended for
women with high risk of NTD are 5mg/d (adopted by
27·8 % of countries and by WHO recommendations) or
4 mg/d (considered by 13·9 % of countries). Some coun-
tries suggest these dosages should be discussed with a
physician (8·3 % of countries and D-A-CH recommenda-
tions) and two countries refer to only ‘higher dosages’.
Although the observed recommendations differ
between countries, the recommendation for folic acid of
400 µg/d before conception until the ﬁrst trimester of
pregnancy is common for most countries (69·4 %)
and WHO.
Countries partially out of this common recommendation
are those that recommended 5mg/d (Brazil) or supple-
mentation throughout pregnancy (Canada, China and USA)
or that did not show the dosage, referring to check with a
health-care provider on the need for taking supplements
and to ensure an adequate folate status (Singapore). This
resembles an attempt to personalize the intervention.
Some countries had incomplete information about
supplementation as follows: dosage was missing in Por-
tugal; time for initiation was absent in Romania; the end
time was missing in South Africa, Portugal and Romania;
and supplementation was not mentioned at all in Russia,
Slovenia and Taiwan.
Taiwan’s website referred that the best method to
ensure sufﬁcient folate for fetal development is to con-
sume foods high in folate on a frequent basis, giving
examples. This perspective contrasted with that of coun-
tries with a focus mainly on supplementation, for example
Netherlands and USA.
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From the analysed countries, ﬁve had mandatory for-
tiﬁcation (Australia, Brazil, Canada, South Africa and USA).
All of these also advised folic acid supplementation.
Given the diversity of the recommendations for
folate from international entities (from D-A-CH, NNR, IOM
and WHO), we opted to build a diagram overlapping
different recommendations with gestational age, peri-
conceptional period and neurulation period, as shown in
Fig. 2.
Discussion
The association between adequate maternal folate levels
during the periconceptional period and the reduction in
congenital anomalies, especially NTD, is well established.
However, achieving an adequate folate status in the
neurulation period is a challenge worldwide, according to
prior studies(2,6,44). To ﬁll this gap, the WHO and many
national health organizations have been developing
recommendations related to folic acid supplementation
and a folate-rich diet. Some countries have also imple-
mented mandatory folic acid fortiﬁcation.
In public health it is indispensable to communicate
widespread clear and unique messages among health
professionals and the general public, once the general
public is becoming more interested in a topic, to judge the
information provided by health professionals.
The question of folate adequacy seeking NTD preven-
tion is very interesting, because the critical period for that
adequacy is the ﬁrst six gestational weeks(2) when the
majority of women do not know they are pregnant, even
in planned pregnancies (exceptions would be medically
assisted pregnancies). Some authors advocate that, ideally,
a correct diet would supply adequate intakes, but this is
not the reality for all(17). Supplementation could be a
solution for this deﬁciency, but it is not always effective
because women are often unaware of their pregnancies
during the target period(15,16). Food fortiﬁcation with folic
acid appears a better solution, providing adequate intakes.
So, recommendations should have a clear message
regarding at least two of the three possibilities for an
adequate folate intake: diet, fortiﬁcation and supplements.
Mandatory fortiﬁcation is restricted to countries that opt for
this measure. Others may have voluntary fortiﬁcation and
recent EU legislation was created in order to regulate this
kind of fortiﬁcation(15).
Nowadays, the World Wide Web is available for the
majority of the population in many countries worldwide.
This is an excellent vehicle for giving messages to health
professionals and the rest of the population. For this rea-
son, this source of information was inspected. Initially, it
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Fig. 2 Recommended folate intake and recommended folic acid supplementation for prevention of NTD during the periconceptional
period (NTD, neural tube defects; D-A-CH, Deutschland–Austria–Confoederatio Helvetica (reference values for nutrient intake by
the German Nutrition Society, Austrian Nutrition Society, Swiss Society for Nutrition Research and Swiss Society for Nutrition);
NNR, Nordic Nutrition Recommendations (by Denmark, Finland, Iceland, Norway and Sweden); IOM, Institute of Medicine, Dietary
Reference Intakes; WHO, Vitamin and Mineral Requirements in Human Nutrition(42)). Definition of periconceptional period adapted
from Steegers-Theunissen et al.(44)
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was intended to obtain information for forty-six countries,
but for ten of them it was impossible to reach any infor-
mation on ofﬁcial websites. For the other thirty-six coun-
tries diverse information was obtained. Notwithstanding
that differences should exist among countries regarding
different dietary patterns and different disease pre-
valences, probably there is not a clear rational justiﬁcation
for the disparities observed between countries.
Folate intake recommendations differ between interna-
tional entities: D-A-CH, NNR, Scientiﬁc Committee on
Food, IOM(2,16,38,45,46) and WHO(28,42). A huge amount of
work should be done regarding dietary advice. Public
health efforts should incorporate practical advice on sto-
rage and cooking to increase folate intake, helping to
optimize folate status(47), as well as recommendations on
dietary pattern(48). A prudent dietary pattern, even in the
era of fortiﬁcation, may decrease the risk of NTD and
some heart defects in non-users of folic acid(48). In addi-
tion to folate, other micronutrients may decrease the risk
of NTD occurrence(49) and once again promoting a heal-
thy diet has several beneﬁts. Furthermore, the practice of a
Western diet by mothers increases the risk of offspring
with a cleft lip or cleft palate approximately twofold(50). A
high preconceptional intake of nutrients predominantly
present in fruits and vegetables reduces the risk of off-
spring affected by orofacial cleft(51). Fast food may
increase the risk of NTD(52).
With the present study we drew a roadmap of the
recommendations about folate and folic acid intake before
and during pregnancy in several countries worldwide
(developed countries and emerging economies) and we
also included WHO recommendations because it is plau-
sible that many other countries consider them. The
recommendations differ between countries, although the
majority (66·7 %) recommend folic acid supplements of
400 µg/d, in the periconceptional period, combined with a
folate-rich diet. A small number of countries emphasize
the importance of a healthy diet naturally rich in folate
with no need for folic acid supplementation. According to
some authors(48), this advice should be the main in all
recommendations for NTD prevention(47), namely
because a healthy diet also supplies other micronutrients
that may decrease the risk of NTD occurrence(49). At the
other end of the spectrum, some countries advise sup-
plementation and have mandatory folic acid fortiﬁcation.
It seems to be consensual that women at high risk of NTD
beneﬁt from higher dosages (4–5mg/d) of folic acid sup-
plementation(4,26,53,54). However, not all cases of NTD are
preventable by increasing the folic acid intake(55). Several
other lifestyle and environmental factors as well as genetic
variations may have an inﬂuence, possibly by affecting one-
carbon metabolism and thus epigenetic events(27). Known
risk factors for NTD are genetic (about 60%(2)), chronic
alcohol intake(54), smoking(53), use of certain drugs (e.g.
carbamazepine, phenobarbital, methotrexate)(53,54), some
pathologies (e.g. epilepsy(54), malabsorption disorders(53,54),
obesity(26,53,54), pre-gestational diabetes(26,53,54)) and perso-
nal or family history of NTD(54).
The current study found that the designations men-
tioned as the adequate period for supplementation differ
between countries. It can be considered that the more
adequate are the ones that include the general designation
‘before conception’ and that refer to ‘planning plus chance
of becoming pregnant’. The designation ‘reproductive age’
is completely broad and if supplementation is suggested
these women could maintain supplementation for large
periods of time, unnecessarily.
Apart from recommendations about supplementation,
some countries have introduced fortiﬁcation and others not.
Surprisingly, one of the countries with mandatory fortiﬁca-
tion (Brazil) recommends supplementation with high doses
of folic acid (5mg/d) for all women and not only for those at
high risk of NTD. But no evidence sustains the recom-
mendation of such doses for all pregnant women(15,45).
Moreover, nowadays the scientiﬁc community is concerned
about potential adverse effects of folic acid fortiﬁcation and
supplementation(2,15,28–32) and adverse pregnancy out-
comes, early or later in life, both in the mother and child,
such as increased birth weight(11–14), insulin resistance in
children(34) and asthma in children(35,36).
Although carcinogenicity induced by high doses of folic
acid is not completely established, this issue should con-
tinue to be studied, since it constitutes a legitimate public
health concern and needs careful monitoring(56). It is
known that through exposure to mandatory food for-
tiﬁcation and vitamin supplement use, a large number of
people have an unprecedented high folic acid intake(57)
and that the capacity of the body to convert folic acid to
5-methyltetrahydrofolate is limited(58). An inverse asso-
ciation was also found between the presence of unmeta-
bolized folic acid in plasma and natural killer cell
cytotoxicity, but further studies on immune function and
health are needed(57). Given the possibility that excessive
folic acid exposure may relate to cancer risk, monitoring
the long-term effect should be warranted(56,59) especially
considering that the vast majority of the population is not
at risk of NTD(59).
In some countries, an effort to personalize intervention
was observed. Some delegated to the physician or the
health provider the decision for supplementation and/or
dosage. In Singapore the importance of folate status, to be
achieved by diet, was mentioned.
It is not easy to know the real intake of folic acid as
supplements in different countries, because many scien-
tiﬁc studies limit this kind of information, providing only
the proportion of supplemented women without reference
to the dose(17,60). In order to measure accurately the real
impact of such recommendations, systematic health
registries are imperative. For instance, regarding con-
genital anomalies, it would be necessary to compile
information regarding miscarriages, medical abortions,
stillbirths and neonates with congenital information,
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information not always easy to aggregate. This is a critical
issue in the comparison among countries with different
levels of accuracy in their registries.
Strengths and weaknesses
As advantages of the present study we can point out its
novelty, considering that all information was searched
from ofﬁcial national health websites, a source of infor-
mation that is widely used and accessible to health pro-
fessionals and the general public. The previous studies
found in the literature included fewer countries and did
not analyse data available on the Internet(16,38). Most data
were ofﬁcially validated, by email, ensuring a better
accuracy. The present study allowed clustering of recom-
mendations to check similarities and disparities within and
between countries, and missing information. Countries
that do not disseminate clear messages were also
identiﬁed.
The study is limited by the lack of information about
excluded countries, other countries worldwide and by
having some countries without ofﬁcial validation, within
which we cannot assure that other recommendations are
emanated. The methodology underlying each recom-
mendation was not analysed, nor was compliance or the
impact of the recommendations in each country.
Public health implications
The role of folate and folic acid during pregnancy being
unquestionable, the present study provides a huge
amount of structured information about worldwide folate
and folic acid recommendations in the periconceptional
period and can form a basis for future discussions on these
issues. Many questions arise at the end of the study, as
follows. What are the reasons behind the different
recommendations? Is there any association between
recommendations and the epidemiology of NTD in the
country? How can we optimize the recommendations,
taking into account different sources (healthy diet, fortiﬁed
foods and supplements)? How can we deal with unplan-
ned pregnancies, other than to recommend supple-
mentation during the entire childbearing age? Are fortiﬁed
foods really a good solution when the entire population is
considered (potential adverse effects)? How to reduce
adverse effects in the mother, child and overall popula-
tion? Is supplementation needed when women have
adequate folate status before pregnancy (and considering
adverse effects)? Will the future hold a place for perso-
nalized recommendations, namely based on blood ana-
lyses of folate status (serum and erythrocyte)?
Conclusions
We conclude that the recommendation more frequently
used worldwide, from analysed countries and the WHO,
about folic acid supplementation in the periconceptional
period is 400 µg/d. The recommendation for folate intake
is in the range of 300–400 µg/d for women of childbearing
age and 500–600 µg/d for pregnant women.
In some countries there are clear indications for the use
of higher dosages among women with higher risk of
congenital anomalies. The recommendation of a healthy
diet, naturally rich in folate, is unanimous. However, big
disparities were seen for the recommendations between
some countries: some recommend supplementation and a
healthy diet plus mandatory fortiﬁcation; in contrast, some
recommend only a healthy diet.
Accurate and ideally evidence-based recommendations
are needed regarding folate and folic acid intake during
the periconceptional period.
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